Inhibition of cardiac guanylate cyclase by doxorubicin and some of its analogs

Doxorubicin, an anthracycline antibiotic and antitumor agent, has cardiotoxic side-effects that limit its therapeutic usefulness. We have demonstrated that the drug inhibits cardiac guanylate cyclase activity in vitro. The biochemical changes following anthracycline treatment are described, and the...

Full description

Saved in:
Bibliographic Details
Published inBiomedicine & pharmacotherapy Vol. 37; no. 7; p. 312
Main Authors Lehotay, D C, Levey, B A, Levey, G S
Format Journal Article
LanguageEnglish
Published France 1983
Subjects
Animals
Doxorubicin - adverse effects
Doxorubicin - analogs & derivatives
Doxorubicin - pharmacology
Guanylate Cyclase - antagonists & inhibitors
Heart - drug effects
Myocardium - enzymology
Rats
Structure-Activity Relationship
Online AccessGet more information

Cover

More Information
Summary:Doxorubicin, an anthracycline antibiotic and antitumor agent, has cardiotoxic side-effects that limit its therapeutic usefulness. We have demonstrated that the drug inhibits cardiac guanylate cyclase activity in vitro. The biochemical changes following anthracycline treatment are described, and the various hypotheses attempting to account for cardiotoxicity in terms of a molecular mechanism are reviewed. It is suggested that inhibition of cardiac guanylate cyclase activity may be a consequence of the increase in free radicals and oxidative damage following treatment with doxorubicin or related compounds.
ISSN:0753-3322